Abstract: The control-monitor, used in combination with a percussive ventilation breathing head and internal reciprocating injector shuttle, includes in a casing a generator, sensory pulse amplitude, frequency and MAP modules and a gas amplitude and pulsatile frequency control knobs. First and second AMP control indicia include a bent conical AMP indicia (a wide span indicating greater amplitude, a narrow span indicating lesser amplitude) and a single waveform with an adjacent double-headed arrow vertical line. First and second F control indicia include a bent conical F indicia (a wide span indicating greater F and a narrow span indicating lesser F) and multiple waveforms with an adjacent double-headed arrow horizontal line.

Abstract: A percussive ventilation breathing head is adapted to be supplied with a flow of pulsatile gas fed to an elongated breathing head body at a proximal end thereof. The breathing head body defines an interior passageway therein. A reciprocating injector shuttle is movably mounted in the breathing head passageway. The shuttle moves distally due to the pulsatile gas, assisted by a diaphragm and a venturi-like jet nozzle which nozzle pulls nebulized aerosol from a depending plenum and a nebulizer attached below the depending plenum. A depending body defines the plenum. The generally cylindrical nebulizer is attached below the depending body. The shuttle is also biased in a proximal direction within the interior passageway and moves proximally due to the bias. The shuttle defines an internal flow passage from a proximal shuttle input port to a distal shuttle output port at the distalmost mouth of the percussive ventilation breathing head body.

Abstract: The control-monitor, used in combination with a percussive ventilation breathing head and internal reciprocating injector shuttle, includes in a casing a generator, sensory pulse amplitude, frequency and MAP modules and a gas amplitude and pulsatile frequency control knobs. First and second AMP control indicia include a bent conical AMP indicia (a wide span indicating greater amplitude, a narrow span indicating lesser amplitude) and a single waveform with an adjacent double-headed arrow vertical line. First and second F control indicia include a bent conical F indicia (a wide span indicating greater F and a narrow span indicating lesser F) and multiple waveforms with an adjacent double-headed arrow horizontal line.

Abstract: The percussive ventilation breathing head is adapted to be supplied with a flow of pulsatile gas fed to an elongated breathing head body at a proximal end thereof. The breathing head body defines an interior passageway therein. A reciprocating injector shuttle is movably mounted in the breathing head passageway. The shuttle moves distally due to the pulsatile gas, assisted by a diaphragm and a venturi-like jet nozzle which nozzle pulls nebulized aerosol from a depending plenum and a nebulizer attached below the depending plenum. A depending body defines the plenum. The generally cylindrical nebulizer is attached below the depending body. The shuttle is also biased in a proximal direction within the interior passageway and moves proximally due to the bias. The shuttle defines an internal flow passage from a proximal shuttle input port to a distal shuttle output port at the distalmost mouth of the percussive ventilation breathing head body.

Abstract: In some embodiments, the present invention is directed to novel targeted contrast agents for magnetic resonance imaging (MRI). The present invention is also directed to methods of making such targeted MRI contrast agents, and to methods of using such MRI contrast agents. Typically, such targeted MRI contrast agents provide enhanced relaxivity, improved signal-to-noise, targeting ability, and resistance to agglomeration. Methods of making such MRI contrast agents typically afford better control over particle size, and methods of using such MRI contrast agents typically afford enhanced blood clearance rates and biodistribution.

Abstract: A set of compounds that includes an active agent-labeled species and a pretargeting conjugate is disclosed. The active agent-labeled species includes a first oligomeric nucleotide or mimic thereof conjugated to a linker having a first moiety coupled with a diagnostic active agent. The pretargeting conjugate includes a second oligomeric nucleotide or mimic thereof conjugated to a targeting species having a targeting moiety capable of binding to a target or a marker produced by or associated with the target. The second oligomeric nucleotide or mimic thereof has a sequence that is at least partially complementary to a sequence of the first oligomeric nucleotide or mimic thereof. Also disclosed are methods of administering the pretargeting conjugate and active agent-labeled species to a subject for diagnosing a disease condition or assessing the effectiveness of a treatment of the disease condition.

Abstract: A set of compounds that includes an active-agent labeled species and a pretargeting conjugate is disclosed. The active agent-labeled species includes a ligand coupled to an active agent. The pretargeting conjugate includes a protein conjugated to a targeting species having a targeting moiety capable of binding to an in-vivo target or a biomarker produced by or associated with the target. The protein and the ligand are covalently attached. Also disclosed are methods of administering the pretargeting species and the active-agent labeled species to a subject for diagnosing or treating a disease condition, or assessing the effectiveness of a treatment of the disease condition.

Abstract: A set of compounds that includes an active-agent labeled species and a pretargeting conjugate is disclosed. The active agent-labeled species includes a ligand coupled to an active agent. The pretargeting conjugate includes a protein conjugated to a targeting species having a targeting moiety capable of binding to an in-vivo target or a biomarker produced by or associated with the target. The protein is substantially free of a cofactor. Also disclosed are methods of administering the pretargeting species and the active-agent labeled species to a subject for diagnosing or treating a disease condition, or assessing the effectiveness of a treatment of the disease condition.